Read the anns 06/12/23
This trial is not sponsored by IMU and not under IMU's control. The Uni London has chosen PD1-Vaxx over Keytruda. Could be because of costs or, as they said, the superior properties of PD1-Vaxx.
Again, market gives a damn, but the scientists approve it.
Investors follow the sp, scientists follow the science. Who will get it right in the end?
GLTA
Ann: Imugene PD1-Vaxx Update, page-174
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |